The key question may be how FDA should assess neutrality of prescription drug maker presentations of information about side effects and effectiveness.

FDA Taking Comments on Rx Ads' Side Effects Content

The requirement that direct-to-consumer TV and radio ads for prescription drugs present information about side effects and contraindications in a clear, conspicuous, neutral manner was in the Food and Drug Administration Amendments Act of 2007.

FDA asked Monday for public comments on how makers of prescription drugs should explain the side effects and contraindications in their direct-to-consumer TV and radio ads for such drugs. The Food and Drug Administration Amendments Act of 2007 required that they communicate the information in the ads in a clear, conspicuous, neutral manner, and the key question may be how FDA should assess neutrality.

FDA said it will accept comments until June 28. They may be submitted, identified by Docket No. FDA-2009-N-0582 and/or RIN 0910-AG27, via www.regulations.gov.

The current regulations on prescription drug ads say they must contain "a true statement" of certain information, including "information in brief summary relating to side effects, contraindications, and effectiveness." The 2007 law added a provision that "in the case of an advertisement for a drug subject to section 503(b)(1) presented directly to consumers in television or radio format and stating the name of the drug and its conditions of use, the major statement relating to side effects and contraindications shall be presented in a clear, conspicuous, and neutral manner." The law gave the HHS secretary 10 months from its enactment to set standards for determining whether an ad's major statement fulfills that requirement.

FDA looked to other agencies' rules, including some from the Federal Trade Commission, Securities and Exchange Commission, and Department of Transportation.

FDA said in the Monday proposed rule that it is not aware of any previous standard or regulation that defines "neutral manner" in the context of required disclosures; the agency said it believes "neutral manner" means "unbiased manner" and has proposed its standards accordingly.

Download Center

HTML - No Current Item Deck
  • Free Safety Management Software Demo

    IndustrySafe Safety Management Software helps organizations to improve safety by providing a comprehensive toolset of software modules to help businesses identify trouble spots; reduce claims, lost days, OSHA fines; and more.

  • The Top 5 Safety and Technology Trends to Watch

    Get the latest on trends you can expect to hear more about in 2019, including continued growth of mobile safety applications, wearable technology, and smart PPE; autonomous vehicles; pending OSHA recordkeeping rulemaking; and increased adoption of international safety standard, ISO 45001.

  • Analyze Incident Data

    Collect relevant incident data, analyze trends, and generate accurate regulatory reports, including OSHA 300, 300A, and 301 logs, through IndustrySafe’s extensive incident reporting and investigation module.

  • Safety Training 101

    When it comes to safety training, no matter the industry, there are always questions regarding requirements and certifications. We’ve put together a guide on key safety training topics, requirements for certifications, and answers to common training questions.

  • Conduct EHS Inspections and Audits

    Record and manage your organization’s inspection data with IndustrySafe’s Inspections module. IndustrySafe’s pre-built forms and checklists may be used as is, or can be customized to better suit the needs of your organization.

  • Industry Safe
comments powered by Disqus

OH&S Digital Edition

  • OHS Magazine Digital Edition - January 2019

    January / February 2019

    Featuring:

    • PREVENTING ERRORS
      Production vs. Safety 
    • EMERGENCY SHOWERS & EYEWASH
      Meeting the Requirements for Emergency Equipment
    • CONSTRUCTION SAFETY
      The State of Contractor Safety
    • FOOT PROTECTION
      The Three Keys to Effective Chemical Management
    View This Issue